Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

341
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
341
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

364
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PROTECT databank a population based linked administrative resource on child maltreatment and intellectual disability with early findings.

Scientific reports·2026
Same author

Trigeminal cold receptors and airflow perception are altered in chronic rhinosinusitis.

Rhinology·2023
Same author

Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.

Neurobiology of disease·2014
Same author

Use of metakaolin to stabilize sewage sludge ash and municipal solid waste incineration fly ash in cement-based materials.

Journal of hazardous materials·2012
Same author

Quantification of uncertainty of experimental measurement in leaching test on cement-based materials.

Journal of environmental management·2011
Same author

Multiscale imaging characterization of dopamine transporter knockout mice reveals regional alterations in spine density of medium spiny neurons.

Brain research·2011

Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
03:49

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

1.3K

Nefazodone: An update.

S C Laizure1, M Cyr

  • 1Department of Clinical Pharmacy, University of Tennessee, Memphis, TN, USA.

International Journal of Psychiatry in Clinical Practice
|June 14, 2014
PubMed
Summary
This summary is machine-generated.

Nefazodone, an antidepressant, offers unique benefits for anxiety with minimal impact on sleep and sexual function. However, careful monitoring for liver toxicity and drug interactions is essential due to its potent CYP3A4 inhibition.

Keywords:
Nefazodone Adverse Reactions Indications Metabolism Drug Interactions

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

2.4K

Related Experiment Videos

Last Updated: Apr 28, 2026

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
03:49

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

1.3K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

2.4K

Area of Science:

  • Pharmacology
  • Clinical Psychiatry
  • Drug Metabolism

Background:

  • Nefazodone presents a novel antidepressant profile.
  • Its clinical significance and unique mechanisms require further elucidation.
  • Existing data suggests minimal impact on sleep architecture and sexual functioning.

Purpose of the Study:

  • To review the characteristics of nefazodone as an antidepressant.
  • To assess its potential in treating anxiety disorders.
  • To highlight safety considerations including drug interactions and hepatic toxicity.

Main Methods:

  • Literature review of nefazodone's pharmacological properties.
  • Analysis of clinical data regarding efficacy and side effects.
  • Examination of pharmacokinetic interactions, particularly with CYP3A4.

Main Results:

  • Nefazodone demonstrates potential anxiolytic activity.
  • It is associated with fewer sleep and sexual side effects compared to other antidepressants.
  • Nefazodone is a strong inhibitor of CYP3A4, necessitating caution with co-administered drugs.
  • Severe hepatic toxicity has been reported, mandating liver function monitoring.

Conclusions:

  • Nefazodone may be a suitable option for patients needing anxiolytic effects while avoiding sexual or sleep disturbances.
  • Vigilant monitoring for hepatic function and potential drug interactions is crucial for safe nefazodone use.